# US 2015/0148376 A1 · Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148376 A1
- Document ID: US20150148376A1
- Status: Published application
- Kind: A1
- Application number: 14/609,122
- Filed: 2015-01-29
- Published: 2015-05-28
- Earliest claimed: 2012-07-20
- Assignees: Bayer Pharma Aktiengesellschaft
- Applicants: Bayer Pharma Aktiengesellschaft
- Inventors: Michael HAHN; Markus Follmann; Walter Hübsch; Eva-Maria Becker; Johannes-Peter Stasch; Joerg Keldenich; Martina Delbeck; Hanna Tinel; Frank Wunder; Joachim Mittendorf; IIdiko Terebesi; Dieter Lang; René Martin
- Web page: https://patentgrep.com/patent/US20150148376A1

## CPC

- C07D 215/48: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A compound of formula (I)
in which
R1 represents hydrogen or fluorine,
L1 represents ethane-1,2-diyl or 1,4-phenylene,
and
A represents a group of the formula
in which
* denotes the respective point of attachment to the remainder of the molecule,
L2 represents straight-chain (C1-C6)-alkanediyl,
L3 represents a bond, —O—, —CH2—, —CH2—CH2— or —CH═CH—,
R2 represents (C1-C4)-alkyl which may be substituted up to six times by fluorine,
or
represents (C3-C6)-cycloalkyl which may be mono- or disubstituted by identical or different radicals selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl and (C1-C4)-alkyl,
or
represents 4- to 6-membered heterocyclyl which contains one or two identical or different hetero ring members selected from the group consisting of N(R4), O, S and S(O)2 where
R4 represents (C1-C4)-alkyl or (C1-C4)-alkylcarbonyl or, in the case that N(R4) represents a ring nitrogen atom by means of which said heterocyclyl is attached to the adjacent phenyl group, is not present,
or
represents 5-membered heteroaryl which contains one, two or three identical or different ring heteroatoms selected from the group consisting of N, O and S and may optionally be fused to a phenyl ring,
where the heteroaryl ring and the optionally fused phenyl ring may each be mono- or disubstituted by identical or different radicals selected from the group consisting of fluorine, chlorine, cyano, difluoromethyl, trifluoromethyl, (C1-C4)-alkyl, difluoromethoxy, trifluoromethoxy and (C1-C4)-alkoxy,
or represents chlorine,
and
R3A, R3B, R3C and R3D independently of one another represent hydrogen or a substituent selected from the group consisting of fluorine, chlorine, bromine, cyano, (C1-C4)-alkyl, difluoromethyl, trifluoromethyl, (C1-C4)-alkoxy, difluoromethoxy and trifluoromethoxy,
and salts, solvates and solvates of the salts thereof.

### Claim 11 (depends on 10)

The compound of claim 10, in which
R1 represents hydrogen or fluorine,
L1 represents ethane-1,2-diyl or 1,4-phenylene,
and
A represents a group of the formula
in which
* denotes the respective point of attachment to the remainder of the molecule,
L2 represents straight-chain (C3-C5)-alkanediyl,
L3 represents a bond, —CH2—CH2— or —CH═CH—,
R2 represents (C1-C4)-alkyl which may be substituted up to three times by fluorine,
or
represents cyclopentyl or cyclohexyl which may be mono- or disubstituted by identical or different radicals selected from the group consisting of fluorine, methyl and trifluoromethyl,
or
represents 5- or 6-membered heterocyclyl of the formula
in which
** denotes the respective point of attachment to the adjacent phenyl group
and
R4 represents methyl, acetyl or propionyl,
or
represents 5-membered heteroaryl selected from the group consisting of 1,2-oxazolyl, 1,3-oxazolyl, 1,2-thiazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl and 1,3,4-thiadiazolyl,
where the heteroaryl groups mentioned may each be substituted by methyl or trifluoromethyl
and
where 1,2-oxazolyl, 1,3-oxazolyl, 1,2-thiazolyl and 1,3-thiazolyl may be fused with a phenyl ring which for its part may be substituted by fluorine, chlorine, cyano, methyl, trifluoromethyl or trifluoromethoxy,
R3A represents hydrogen, fluorine, chlorine, methyl or trifluoromethyl,
R3B represents hydrogen, fluorine, chlorine, methyl, trifluoromethyl, methoxy or trifluoromethoxy,
R3C represents hydrogen, fluorine, chlorine, methyl or trifluoromethyl,
and
R3D represents hydrogen, fluorine, chlorine, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy,
and salts, solvates and solvates of the salts thereof.

### Claim 12 (depends on 10)

The compound of claim 10, in which
R1 represents hydrogen or fluorine,
L1 represents ethane-1,2-diyl or 1,4-phenylene,
and
A represents a group of the formula
in which
* denotes the respective point of attachment to the remainder of the molecule,
L2 represents straight-chain (C3-C5)-alkanediyl,
L3 represents a bond, —CH2—CH2— or —CH═CH—,
R2 represents (C1-C4)-alkyl which may be substituted up to three times by fluorine,
or
represents cyclopentyl or cyclohexyl which may be mono- or disubstituted by identical or different radicals selected from the group consisting of fluorine, methyl and trifluoromethyl,
or
represents 6-membered heterocyclyl of the formula
in which
** denotes the point of attachment to the adjacent phenyl group
and
R4 represents methyl, acetyl or propionyl,
or
represents 1,3-benzoxazol-2-yl, 1,2-benzoxazol-3-yl or 1,3-benzothiazol-2-yl which may be substituted by a radical selected from the group consisting of fluorine, chlorine, cyano, methyl, trifluoromethyl and trifluoromethoxy,
R3A represents hydrogen, fluorine, chlorine, methyl or trifluoromethyl,
R3B represents hydrogen, fluorine, chlorine, methyl, trifluoromethyl or trifluoromethoxy,
R3C represents hydrogen, fluorine, chlorine, methyl or trifluoromethyl,
and
R3D represents hydrogen, fluorine, chlorine, cyano, methyl, trifluoromethyl or trifluoromethoxy, and salts, solvates and solvates of the salts thereof.

### Claim 13 (depends on 10)

The compound of claim 10, in which
R1 represents hydrogen or fluorine,
L1 represents ethane-1,2-diyl or 1,4-phenylene,
and
A represents a group of the formula
in which
* denotes the respective point of attachment to the remainder of the molecule,
L3 represents a bond or —CH2—CH2—,
R2 represents tert-butyl, cyclohexyl, 4-(trifluoromethyl)cyclohexyl or 1,3-benzoxazol-2-yl which may be substituted by chlorine, cyano, methyl or trifluoromethyl,
R3C represents hydrogen or chlorine,
and
R3D represents hydrogen, fluorine or trifluoromethyl,
and salts, solvates and solvates of the salts thereof.

### Claim 14 (depends on 10)

A process for preparing the compound of claim 10, comprising either
[A] reacting a compound of the formula (II)
in which R1 and L1 have the meanings given in claim 10
and
T1 and T2 are identical or different and represent (C1-C4)-alkyl,
in the presence of a base with a compound of the formula (III)
in which A has the meanings given in claim 10
and
X1 represents a leaving group
or
[B] reacting a compound of the formula (IV)
in which R1 and A have the meanings given in claim 10
and
T2 represents (C1-C4)-alkyl,
in the presence of a base with a compound of the formula (V)
in which L1 has the meaning given in claim 10,
T1 represents (C1-C4)-alkyl,
and
X2 represents a leaving group
and converting the resulting compound of the formula (VI)
in which R1, A, L1, T1 and T2 have the meanings given above,
by hydrolysis of the ester groupings —C(O)OT1 and —C(O)OT2 into the corresponding dicarboxylic acid of the formula (I)
wherein the compounds of the formula (I) obtained in this manner are optionally separated into their enantiomers and/or diastereomers and/or optionally converted with the appropriate (i) solvent and/or (ii) base or acid into their solvates, salts and/or solvates of the salts.

### Claim 15 (depends on 10)

A pharmaceutical composition comprising the compound of claim 10 and at least one inert non-toxic pharmaceutically suitable auxiliary.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, further comprising at least one active compound selected from the group consisting of an organic nitrate, a NO donor, a PDE 5 inhibitor, a prostacyclin analogue, an IP receptor agonist, an endothelin receptor antagonist, a guanylate cyclase stimulator, a tyrosine kinase inhibitor, an anti-obstructive agent, an anti-inflammatory and/or immunosuppressive agent, an antithrombotic agent, an agent for lowering blood pressure, and an agent that alters fat metabolism.

### Claim 17 (depends on 10)

A method for the treatment and/or prevention of primary and secondary forms of pulmonary hypertension, heart failure, angina pectoris, hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and arteriosclerosis comprising administering an effective amount of a compound of claim 10 to a human or animal in need thereof.

### Claim 18 (depends on 15)

A method for the treatment and/or prevention of primary and secondary forms of pulmonary hypertension, heart failure, angina pectoris, hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and arteriosclerosis comprising administering an effective amount of a pharmaceutical composition of claim 15 to a human or animal in need thereof.

### Claim 19 (depends on 10)

The compound according to claim 10, wherein the compound has the formula:

### Claim 20 (depends on 10)

The compound according to claim 10, wherein the compound has the formula:
or a salt, solvate, or solvate of the salt thereof.

### Claim 21 (depends on 19)

A pharmaceutical composition comprising the compound of claim 19 and at least one inert non-toxic pharmaceutically acceptable auxiliary.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, further comprising at least one active compound selected from the group consisting of an organic nitrate, a NO donor, a PDE 5 inhibitor, a prostacyclin analogue, an IP receptor agonist, an endothelin receptor antagonist, a guanylate cyclase stimulator, a tyrosine kinase inhibitor, an anti-obstructive agent, an anti-inflammatory and/or immunosuppressive agent, an antithrombotic agent, an agent for lowering blood pressure, and an agent that alters fat metabolism.

### Claim 23 (depends on 19)

A method for the treatment and/or prevention of primary and secondary forms of pulmonary hypertension, heart failure, angina pectoris, hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and arteriosclerosis comprising administering an effective amount of a compound of claim 19 to a human or animal in need thereof.

### Claim 24 (depends on 20)

A pharmaceutical composition comprising the compound of claim 20 and at least one inert non-toxic pharmaceutically acceptable auxiliary.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, further comprising at least one active compound selected from the group consisting of an organic nitrate, a NO donor, a PDE 5 inhibitor, a prostacyclin analogue, an IP receptor agonist, an endothelin receptor antagonist, a guanylate cyclase stimulator, a tyrosine kinase inhibitor, an anti-obstructive agent, an anti-inflammatory and/or immunosuppressive agent, an antithrombotic agent, an agent for lowering blood pressure, and an agent that alters fat metabolism.

### Claim 26 (depends on 20)

A method for the treatment and/or prevention of primary and secondary forms of pulmonary hypertension, heart failure, angina pectoris, hypertension, thromboembolic disorders, ischaemias, vascular disorders, impaired microcirculation, renal insufficiency, fibrotic disorders and arteriosclerosis comprising administering an effective amount of a compound of claim 20 to a human or animal in need thereof.
